Altamira Therapeutics Ltd
altamiratherapeutics.comWhat Do They Do?
Develops peptide-based particles that carry RNA into tissues, and experimental RNA medicines for cancer and rheumatoid arthritis, for biopharmaceutical companies.
20-F for FY2024, filed Apr 30, 2025We are a preclinical-stage biopharmaceutical company developing and supplying peptide-based nanoparticle technologies for efficient RNA…View ↗
We are aiming to license the xPhore technology to companies in the biopharmaceutical industry for use with their own RNA molecules…View ↗
Demonstrate proof of concept with xPhore. Based on positive results obtained with OligoPhore delivering various siRNA payloads in more than…View ↗
Who Are Their Customers?
The company aims to license its RNA-delivery technology to biopharmaceutical companies for use with their own RNA molecules, with formulation and process-development support.
20-F for FY2024, filed Apr 30, 2025
How Are They Changing?
From ear drugs to RNA delivery
The earlier report covered inner-ear drugs, Bentrio and an emerging RNA-delivery effort; the latest centers on RNA delivery and its cancer and rheumatoid-arthritis programs, while part of Bentrio has been spun off.
20-F for FY2021, filed Apr 12, 2022 20-F for FY2024, filed Apr 30, 2025History and development of the CompanyView ↗
Who Do They Compete With?
Competes with Acuitas Therapeutics, Aposense, Bio-Path Holdings, Biodrone Therapeutics, Entos Pharmaceuticals, Genevant Sciences, NanoVation Therapeutics, N4 Pharma, Ovensa, ReCode Pharmaceuticals, Sirnaomics, Amgen, Mirati Therapeutics, Genentech, Eli Lilly, Revolution Medicine, Silexion Therapeutics, Boehringer Ingelheim, AbbVie, and Johnson & Johnson
20-F for FY2024, filed Apr 30, 2025There are several companies offering commercial- or developmental-stage technologies for delivering RNA payloads to extrahepatic cells.…View ↗
Loading...
